Forward Therapeutics, the first biotech from Curie.Bio, raises $50M for oral small molecules in immunology
An 18-month-old Florida biotech has raised a $50 million Series A to wade into the hot immunology and inflammation (I&I) field with oral small molecules.
Forward Therapeutics unveiled the financing from BVF Partners, RA Capital Management and OrbiMed on Wednesday morning. The startup will use the funds to gather Phase I data within three years for its lead drug candidate, CEO Toufike Kanouni told Endpoints News.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.